by Sharad Khusal The life sciences business model is changing. In the past, companies typically worked with fewer partners, most often collaborating only with the physician, or indirectly, with patients. That later expanded to liaising with academia and the contract research organizations (CROs) directly affiliated with them. Today, those walls have come down and pharmaceutical […]
by Gireesh Gaonkar As a medicinal product moves from R&D into approval and manufacturing, it must deal with a complex and dispersed distribution network and a global network of manufacturing sites, some of which may be using old, noncomputer numerical control-enabled (non-CNC-enabled) machinery. Advances in technologies and the digital value chain create new pathways for […]
By George Mathew, MD Efforts to address the opioid crisis are manyfold. Prescription drug monitoring programs (PDMPs), grant programs, the use of waiver programs, and the implementation of initiatives similar to patient-centered medical homes are all being used by states with varying degrees of success. These programs are, however, just the tip of the iceberg […]
La digitalización en sectores como el de los seguros, las telecomunicaciones y la banca han cambiado completamente la manera en la que los ciudadanos consumen servicios, así como sus expectativas: esperan servicios integrados, atención ininterrumpida (24×7), personalizada, y que responda a sus preferencias de manera inmediata por diversos canales. La digitalización de los servicios de […]
by Gireesh Gaonkar The life sciences value chain — from R&D to manufacturing to marketing and sales — has long battled with addressing the challenges presented by silos, a complex network of global partners and affiliates, and as a result, inconsistent and disconnected ways to manage the large pool of data generated. But with the […]
by Dawn Waite Digital platforms are taking the business world by storm, paving the way for new ways to work — thanks to better interoperability and greater flexibility of advanced technology. But digital platforms aren’t without their complexities. Building an on-premises digital solution is costly and requires having a pool of talent available to scale […]
By Beth Slamowitz Pharmacists, who are considered among the most accessible and trusted health professionals, can answer questions about reducing the risk of overdose, what to do in case of an overdose and where to seek help with addiction management services. Pharmacists are the gatekeepers for prescription painkillers and play a key role in preventing […]
By Sadia Ahmed and Marcy Miller, DXC Life Sciences The world of the electronic Common Technical Document (eCTD) is closing in on life sciences companies, irrespective of size. The U.S. Food and Drug Administration (FDA) now requires the use of eCTD for all New Drug Applications (NDAs), Abbreviated NDAs, and Biologics License Applications (BLAs), and […]
By Jeanie Kwon and Leslie Wan, DXC Life Sciences Digitization of the regulatory platform has conferred significant benefits for life sciences companies, but it has also brought new challenges, since our industry is heavily governed by standard operating procedures and validated systems to meet regulations. Add to regulations, global language barriers, entrenched ways of working […]
By Sharad Khusal, Global Head, Life Sciences Build Team, DXC The message for the life sciences industry is loud and clear: It must manage costs, demonstrate real-world value of its products, and find new ways to innovate and respond to customer demands. It was a discussion that resonated during the Life Sciences User Group meeting […]
